Evogene
EVGN
26 hedge funds and large institutions have $1.2M invested in Evogene in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 6 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
0.04% less ownership
Funds ownership: 0.39% → 0.35% (-0.04%)
4% less capital invested
Capital invested by funds: $1.25M → $1.2M (-$50.8K)
10% less funds holding
Funds holding: 29 → 26 (-3)
17% less call options, than puts
Call options by funds: $19K | Put options by funds: $23K
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$93.2K |
| 2 |
Morgan Stanley
New York
|
+$35.3K |
| 3 |
VF
Virtu Financial
New York
|
+$14.7K |
| 4 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
+$13.1K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$8.11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$159K |
| 2 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
-$68K |
| 3 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$33.6K |
| 4 |
SIGI
Susquehanna International Group (Ireland)
Dublin,
Ireland
|
-$21K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$8K |
EVGN Hedge Fund Activity: Q3 2022 in Review
26 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q3 2022, worth a combined $1.2M — down 4.1% from $1.25M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of EVGN and 3 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 7 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $93.2K. The largest seller was Renaissance Technologies, cutting an estimated $159K.
- 26 institutional investors held Evogene (EVGN) as of Q3 2022, down from 29 in Q2 2022.
- Funds reported $1.2M of Evogene stock for Q3 2022, down 4.1% quarter-over-quarter.
- 3 funds opened new Evogene positions in Q3 2022 and 6 closed out, a net change of -3 holders.
- The largest Evogene buyer in Q3 2022 was Citadel Advisors, an estimated $93.2K added.
- The largest Evogene seller in Q3 2022 was Renaissance Technologies, an estimated $159K sold.
Based on aggregated 13F filings for Q3 2022.